<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006234</url>
  </required_header>
  <id_info>
    <org_study_id>1474.00</org_study_id>
    <secondary_id>FHCRC-1474.00</secondary_id>
    <secondary_id>CHMC-S-6007</secondary_id>
    <secondary_id>NCI-G00-1842</secondary_id>
    <secondary_id>CDR0000068159</secondary_id>
    <nct_id>NCT00006234</nct_id>
  </id_info>
  <brief_title>Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone</brief_title>
  <official_title>A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive drugs, such as holmium Ho 166 DOTMP, may carry radiation directly to&#xD;
      cancer cells and not harm normal cells. Peripheral stem cell transplantation may be able to&#xD;
      replace stem cells that were destroyed by the radioactive drug.&#xD;
&#xD;
      PURPOSE: This Phase I/II trial is studying the effectiveness of holmium Ho 166 DOTMP followed&#xD;
      by peripheral stem cell transplantation in treating patients who have metastatic Ewing's&#xD;
      sarcoma or rhabdomyosarcoma that has spread to the bone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dosimetry of holmium Ho 166 DOTMP in patients with metastatic Ewing's&#xD;
           sarcoma family of tumors or rhabdomyosarcoma with bone metastases.&#xD;
&#xD;
        -  Provide treatment with holmium Ho 166 DOTMP for these patients.&#xD;
&#xD;
        -  Determine the toxicity and pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the change in tumor cell content in peripheral blood and bone marrow after&#xD;
           treatment with this drug in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive a trace dose of holmium Ho 166 DOTMP IV over 10 minutes on day -7&#xD;
      and an assigned dose over 10 minutes on day 0. Autologous peripheral blood stem cells are&#xD;
      infused on days 7-10.&#xD;
&#xD;
      Patients are followed at least weekly for 4 weeks and then monthly for 1 year or until&#xD;
      disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Metastatic Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>holmium Ho 166 DOTMP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Ewing's sarcoma family of tumors or rhabdomyosarcoma with&#xD;
             bone metastases&#xD;
&#xD;
               -  Refractory to conventional therapy OR&#xD;
&#xD;
               -  Responsive to conventional therapy with osseous metastases at diagnosis that are&#xD;
                  extensive enough to preclude concurrent radiotherapy to all sites&#xD;
&#xD;
          -  Soft tissue, pulmonary, and/or bone marrow metastases in addition to cortical bone&#xD;
             allowed&#xD;
&#xD;
               -  Extraosseous sites of disease allowed if amenable to surgical resection or&#xD;
                  external beam radiotherapy&#xD;
&#xD;
          -  No patients under 10 years old with embryonal rhabdomyosarcoma&#xD;
&#xD;
          -  Adequate peripheral blood stem cells stored&#xD;
&#xD;
               -  At least 2,500,000 CD34+ cells/kg&#xD;
&#xD;
          -  No impending bone fracture or spinal cord compression&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  12 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL (RBC transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGOT no greater than 2.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Radioisotope glomerular filtration rate, iothalamate clearance, or creatinine&#xD;
             clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 3 months since prior bone marrow or peripheral blood stem cell&#xD;
             transplantation (6 months for total body irradiation conditioning) and recovered&#xD;
&#xD;
          -  At least 1 week since prior cytokines&#xD;
&#xD;
          -  No immunomodulators during and for at least 4 weeks after study&#xD;
&#xD;
          -  No concurrent cytokines&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  No more than 3 prior systemic chemotherapy regimens&#xD;
&#xD;
          -  No systemic chemotherapy during and for at least 4 weeks after study&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior maximum tolerable radiotherapy (greater than 30 Gy) to the spinal cord&#xD;
&#xD;
          -  No prior therapeutic doses of bone-seeking radiopharmaceutical (e.g., samarium Sa 153&#xD;
             lexidronam pentasodium EDTMP)&#xD;
&#xD;
          -  No radiotherapy during and for at least 4 weeks after study&#xD;
&#xD;
               -  Local radiotherapy to any tumor site allowed provided at least 1 evaluable lesion&#xD;
                  is untreated&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No surgical resection of all bone metastases evaluable by PET during and for 1 month&#xD;
             after study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Hawkins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>bone metastases</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

